Citadel Advisors’s DNA X Inc SONM Stock Holding History

Citadel Advisors’s Portfolio SONM Stock Details SONM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-35	Closed	-$35K	–	14591
2021 Q2	$35K	Buy	35 +24	+218%	+$26.1K	﹤0.01%	13451
2021 Q1	$17K	Buy	+11	New	+$19.4K	﹤0.01%	13077

Other funds holding SONM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

DAS

Dynamic Advisor Solutions Phoenix, Arizona $3.53B AUM 22.61% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Citadel Advisors's SONM Position: Q3 2021 in Review

Citadel Advisors sold out of DNA X Inc (SONM) in Q3 2021, closing a stake of 35 shares — an estimated $35K sold.

Citadel Advisors first reported a position in SONM in Q1 2021 and held it in 2 quarters. The position peaked at $35K in Q2 2021. 11 funds tracked by Wall St. Rank hold SONM as of Q3 2021.

Citadel Advisors reported no remaining DNA X Inc position as of Q3 2021 after selling out during the quarter.
Citadel Advisors sold 35 DNA X Inc shares in Q3 2021, an estimated $35K.
Citadel Advisors first reported a position in DNA X Inc in Q1 2021 and held it in 2 quarters.
Citadel Advisors's DNA X Inc position peaked at $35K in Q2 2021.
11 funds tracked by Wall St. Rank held DNA X Inc as of Q3 2021.

Based on Citadel Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.